Trial Profile
Phase III trial of norovirus bivalent vaccine-Takeda for the prevention of norovirus infections
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 14 Jun 2022
Price :
$35
*
At a glance
- Drugs HIL 214 (Primary)
- Indications Norovirus infections
- Focus Therapeutic Use
- 08 Jun 2022 According to a HilleVax media release, the company secured the capital needed to fund this study.
- 04 Feb 2015 New trial record
- 02 Feb 2015 Takeda plans to initiate this global phase III trial in fiscal years 2015-2016, according to a media release.